Peptides for Weight Loss: The 2026 Buyer's Guide to GLP-1s, Visceral Fat, and Metabolic Peptides
Peptides for weight loss work through three different mechanisms, and picking the right one starts with understanding which mechanism fits your goal. GLP-1 agonists like semaglutide and tirzepatide reduce appetite at the brain and gut. Metabolic peptides like AOD-9604, MOTs-C, and 5-Amino 1MQ increase how efficiently your cells burn fuel. Tesamorelin reduces visceral abdominal fat through GH release. This guide walks all eight prescription options honestly.
14 min read · Updated May 28, 2026
Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed May 28, 2026.The short answer
Not every weight loss peptide does the same thing. The 2026 prescription peptide options work through three distinct mechanisms, and matching the mechanism to your goal is the first decision.
If your goal is the largest possible weight loss: tirzepatide (15 to 22 percent body weight in trials) or semaglutide (10 to 15 percent) are the dominant tools. Both are GLP-1 agonists that suppress appetite.
If your goal is visceral abdominal fat reduction: tesamorelin has the strongest evidence base. It is FDA-approved as Egrifta specifically for visceral adipose tissue (VAT) reduction and produces 15 to 18 percent VAT reduction over 26 weeks.
If your goal is metabolic optimization without appetite changes: AOD-9604, 5-Amino 1MQ, MOTs-C, or the combination Lean Stack fit better. These work at the fat cell rather than at the brain and gut.
All eight options below are compounded by Optimal Balance Pharmacy at 503A wholesale pricing under a prescription written by an RxPepsDirect licensed provider in 28 states.
Three mechanisms, three answers
The most common mistake patients make when researching peptides for weight loss is treating them all as variations on the same drug. They are not. The three classes work in completely different ways, and the right answer for one patient is often wrong for another.
Mechanism 1: Appetite suppression (GLP-1 agonists)
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It tells the brain you are full, slows gastric emptying, and improves insulin sensitivity. GLP-1 agonists like semaglutide and tirzepatide are synthetic analogs that activate this same pathway for longer. The result is reduced appetite, smaller portions, slower eating, and substantial weight loss over months.
GLP-1 agonists produce the largest documented weight loss of any class. They are also the most studied, with millions of patient-years of safety data through their FDA-approved branded versions (Ozempic, Wegovy, Mounjaro, Zepbound).
Mechanism 2: Metabolic boost (NNMT inhibitors, GH fragments, mitochondrial peptides)
The second class works at the fat cell directly. Peptides like 5-Amino 1MQ inhibit the NNMT enzyme that fat cells overexpress in metabolic dysfunction, restoring intracellular NAD+ and mitochondrial function. AOD-9604 is a fragment of growth hormone that drives lipolysis (fat breakdown) without the systemic GH side effects. MOTs-C is a mitochondrial-derived peptide that improves cellular energy use through AMPK activation.
These peptides produce smaller absolute weight loss than GLP-1s but work without appetite suppression and without GI side effects. They fit patients who want metabolic optimization, who do not tolerate GLP-1s, or who want to add a complementary mechanism to an existing GLP-1 protocol.
Mechanism 3: Visceral fat reduction (GHRH analogs)
Visceral fat (the fat inside the abdominal cavity, around the organs) is metabolically distinct from subcutaneous fat. It is more inflammatory, more insulin-resistant, and more strongly associated with cardiovascular and metabolic risk. Standard weight loss often reduces both compartments but does not preferentially target visceral fat.
Tesamorelin is a GHRH analog that triggers pulsatile GH release. Growth hormone preferentially mobilizes visceral adipose tissue. The FDA approved tesamorelin (as Egrifta) for HIV-associated lipodystrophy specifically because of its documented effect on visceral fat. Trials show 15 to 18 percent VAT reduction over 26 weeks at therapeutic doses, with preservation or modest gain of lean mass.
GLP-1 agonists: semaglutide and tirzepatide
The dominant class for total weight loss. Both peptides are FDA-approved as branded drugs and dispensed as compounded versions by 503A pharmacies at substantially lower cost.
Semaglutide
The original GLP-1 agonist proven for chronic weight management. In the STEP trials, semaglutide at 2.4mg weekly produced average weight loss of 14.9 percent of body weight over 68 weeks. RxPepsDirect prescribes compounded semaglutide starting at $25 per vial with two carrier formulations: B-12 (the standard) and B-6 plus glycine (the alternative for sensitive patients). Compare compounded semaglutide telehealth options and see the semaglutide product page for current pricing.
Tirzepatide
The next-generation dual agonist hitting both GLP-1 and GIP receptors. In the SURMOUNT trials, tirzepatide at 15mg weekly produced average weight loss of 20.9 percent of body weight over 72 weeks. Tirzepatide is the stronger primary tool for patients who can tolerate it. RxPepsDirect prescribes compounded tirzepatide starting at $45 per vial. See the compounded tirzepatide vs Mounjaro vs Zepbound comparison and the tirzepatide product page.
For a head-to-head between the two, see semaglutide vs tirzepatide for weight loss.
Tesamorelin: the visceral fat peptide
Tesamorelin deserves its own section because it solves a problem GLP-1s do not specifically target: visceral abdominal fat.
Tesamorelin is a 44-amino acid GHRH analog with stabilizing modifications that extend its half-life. It triggers pulsatile growth hormone release from the pituitary. The released GH preferentially mobilizes visceral adipose tissue, the metabolically dangerous fat inside the abdominal cavity around the liver, intestines, and pancreas.
The FDA approved tesamorelin (brand name Egrifta) in 2010 for HIV-associated lipodystrophy. In the pivotal trials, tesamorelin produced 15 to 18 percent visceral fat reduction over 26 weeks of daily dosing, with preservation or modest gain of lean mass and no significant change in subcutaneous fat. The effect on visceral fat is well-documented and reproducible.
Off-label use for non-HIV patients with visceral adiposity is permitted under physician judgment. RxPepsDirect prescribes compounded tesamorelin at $100 per 15mg vial. Standard dose is 1mg to 2mg subcutaneously daily, typically on a 5-on / 2-off weekly cycle. Note: tesamorelin lives in our muscle-growth catalog category because the mechanism is GH release, but the primary clinical use is visceral fat reduction.
See the tesamorelin product page and the full tesamorelin buyer's guide for clinical detail, dosing protocol, and Egrifta vs compounded pricing comparison.
Metabolic peptides: AOD-9604, 5-Amino 1MQ, MOTs-C
AOD-9604
AOD-9604 is a synthetic fragment of human growth hormone (the last 16 amino acids of the C-terminus of hGH). It carries the lipolytic activity of GH (fat breakdown) without the metabolic and growth side effects of the full molecule. Animal studies show direct effects on adipose tissue lipolysis and reduced fat storage. RxPepsDirect prescribes AOD-9604 at $80 per 6mg vial. Standard dose is 250 to 500mcg daily by subcutaneous injection. See the AOD-9604 product page.
5-Amino 1MQ
5-Amino 1MQ is a small-molecule NNMT inhibitor that boosts intracellular NAD+ in fat cells and activates mitochondrial fatty acid oxidation. Animal data is strong and consistent; human clinical trials are still early. RxPepsDirect prescribes 5-Amino 1MQ at $80 per 25mg vial. Standard dose is 1mg daily by subcutaneous injection. See the full 5-Amino 1MQ buyer's guide for the honest evidence picture and the 5-Amino 1MQ product page.
MOTs-C
MOTs-C is a mitochondrial-derived peptide that activates AMPK signaling and improves cellular energy use, insulin sensitivity, and metabolic flexibility. MOTs-C is included in the Lean Stack combination product (see below) rather than offered as a standalone SKU.
Lean Stack: the 4-peptide combination
Lean Stack combines AOD-9604, MOTs-C, Tesamorelin, and Ipamorelin in a single injectable vial. The rationale: four complementary mechanisms in one daily injection rather than four separate vials.
- AOD-9604 drives direct lipolysis without GH side effects
- MOTs-C upregulates mitochondrial function and AMPK signaling
- Tesamorelin targets visceral adipose through GHRH-mediated GH release
- Ipamorelin adds a ghrelin-receptor GH pulse for additive effect
RxPepsDirect prescribes Lean Stack at $125 per 36mg vial. Standard dose is 20 units daily for 5 days, 2 days off. The combo fits patients who want broad metabolic action without juggling four separate prescriptions. See the Lean Stack product page.
Tesofensine: the oral option
Tesofensine is a triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) developed in Denmark for weight loss. European Phase 2 trials showed 9.2 percent average weight loss at 0.5mg daily over 24 weeks, comparable to early-generation oral weight loss drugs. Tesofensine is taken orally as capsules rather than injection.
Tesofensine is approved for clinical use in Mexico and is available through 503A compounding pathways in the United States. RxPepsDirect prescribes tesofensine at $2.25 per capsule. The standard dose is 0.25 to 0.5mg daily. Side effects include insomnia, dry mouth, mild blood pressure elevation, and reduced appetite. Tesofensine fits patients who want an oral option, or who do not tolerate GLP-1 GI side effects.
Lipotropic injections: Lipo-B and Lipo-C
Lipotropic injections are not standalone weight loss agents but are commonly prescribed as adjuncts to support fat metabolism, energy, and B-vitamin status during a weight loss protocol.
- Lipo-B combines methionine, inositol, and choline (MIC) with cyanocobalamin (B-12). $30 per 10mL vial.
- Lipo-C adds L-carnitine to the MIC plus B-12 base for additional fatty acid transport support. $35 per 10mL vial.
Lipotropics typically run alongside a GLP-1 or metabolic peptide protocol rather than as primary therapy. The evidence base for weight loss as a standalone agent is modest, but they reliably support energy and B-vitamin status during caloric restriction.
Comparison table: all 8 options
| Peptide | Mechanism | Typical weight loss | Appetite effect | RxPeps price |
|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | 10 to 15% body weight | Strong suppression | From $25 / vial |
| Tirzepatide | GLP-1 + GIP agonist | 15 to 22% body weight | Strong suppression | From $45 / vial |
| Tesamorelin | GHRH analog (visceral fat) | 15 to 18% visceral fat | Minimal | $100 / 15mg vial |
| AOD-9604 | GH fragment (lipolysis) | Modest, adjunct | None | $80 / 6mg vial |
| 5-Amino 1MQ | NNMT inhibitor | Modest, adjunct | None | $80 / 25mg vial |
| Lean Stack | 4-peptide metabolic combo | Moderate, broad action | Mild (Ipa component) | $125 / 36mg vial |
| Tesofensine | Triple monoamine reuptake | 9% body weight | Moderate suppression | $2.25 / capsule |
| Lipo-C | Lipotropic adjunct | Adjunct only | None | From $35 / 10mL |
Choosing framework: which peptide for which goal
If your goal is maximum weight loss
Start with tirzepatide. The published weight loss magnitude is larger than any other prescription weight loss option, and the safety database is large because the same molecule is FDA-approved as Mounjaro and Zepbound. Tirzepatide fits patients who can tolerate GI side effects and want the strongest primary tool.
If you prefer a more conservative GLP-1 start
Start with semaglutide. Smaller average weight loss than tirzepatide but the longest safety and efficacy track record in the class. Semaglutide fits patients who want the GLP-1 mechanism with a slightly milder starting position.
If your primary concern is visceral abdominal fat
Tesamorelin is the answer. No other peptide has the specific visceral fat evidence base. Patients with elevated waist circumference, fatty liver, or metabolic syndrome who want a targeted intervention for visceral adiposity should start here. Can be paired with a GLP-1 or used standalone.
If you cannot tolerate GLP-1 side effects
5-Amino 1MQ, AOD-9604, or Lean Stack are the right alternatives. These work without appetite suppression and without GI side effects. Weight loss magnitude is smaller than GLP-1 therapy, but the side effect profile is much cleaner.
If you want an oral option
Tesofensine is the only prescription oral weight loss peptide option. Capsules instead of injections. Side effects are stimulant-pattern (insomnia, dry mouth, blood pressure) rather than GI.
If you want to support an existing protocol
Lipo-C, lipotropics, or B-12 support fat metabolism, energy, and micronutrient status during a primary GLP-1 or peptide protocol. Not standalone agents.
How to get a prescription
- Browse the weight loss peptide catalog and add up to three SKUs to your protocol.
- Complete the medical intake and pay the $39 provider review.
- An RxPepsDirect licensed provider (Dr. Jonathan Snipes, MD or Kim Callender, FNP-BC) reviews your intake within 24 to 48 hours and approves the appropriate protocol for your goals.
- Optimal Balance Pharmacy compounds the prescription, ships pre-reconstituted overnight via FedEx in a reusable cooled travel case.
- Refills are per vial with no auto-billing. Re-request when you need the next one.
Related guides
- Semaglutide vs tirzepatide for weight loss for the GLP-1 head-to-head
- Compounded tirzepatide vs Mounjaro vs Zepbound for the compounded vs branded comparison
- Tesamorelin buyer's guide for the Egrifta vs compounded comparison
- 5-Amino 1MQ buyer's guide for the NNMT inhibitor mechanism
- Glycine vs B-12 carrier for the compounded GLP-1 carrier comparison
- Microdose GLP-1 protocol guide for the conservative starting protocol
- The peptide therapy pillar guide for context on the broader peptide class
Frequently asked questions
- What is the best peptide for weight loss in 2026?
- Tirzepatide produces the largest documented weight loss in published clinical trials, averaging 15 to 22 percent of body weight at therapeutic doses. Semaglutide produces 10 to 15 percent. Both are GLP-1 agonists that work by suppressing appetite. If your goal is the largest possible weight loss and you tolerate GLP-1 side effects, tirzepatide is the strongest single agent. For other goals (visceral fat reduction, metabolic optimization without appetite changes), different peptides fit better.
- What peptide is best for visceral abdominal fat?
- Tesamorelin has the strongest evidence base for visceral fat reduction. It is FDA-approved as Egrifta for HIV-associated lipodystrophy specifically because of its documented effect on visceral adipose tissue (VAT). Published trials show 15 to 18 percent VAT reduction over 26 weeks of therapy. Tesamorelin works by triggering pulsatile GH release that preferentially mobilizes intra-abdominal fat. RxPepsDirect prescribes compounded tesamorelin at $100 per vial through Optimal Balance Pharmacy.
- What is the difference between semaglutide and tirzepatide?
- Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. Tirzepatide produces larger average weight loss in head-to-head trials (15 to 22 percent vs 10 to 15 percent). Side effect profiles are similar; both produce GI symptoms (nausea, constipation) at therapeutic doses. Tirzepatide is generally a stronger primary tool for patients who can tolerate it. See the dedicated semaglutide vs tirzepatide comparison guide.
- Are weight loss peptides safe?
- GLP-1 agonists (semaglutide, tirzepatide) have the largest safety database because they are FDA-approved drugs with millions of patient-years of use. Side effects are well-characterized: nausea, constipation, fatigue, rare pancreatitis, and a thyroid C-cell tumor warning. Tesamorelin is FDA-approved as Egrifta with a defined side effect profile (injection site reactions, mild joint stiffness, possible glucose intolerance). AOD-9604 and 5-Amino 1MQ have strong preclinical safety data and limited human clinical exposure. Tesofensine has European clinical use. All weight loss peptides require provider screening for contraindications.
- Do weight loss peptides cause muscle loss?
- GLP-1 agonists cause meaningful lean mass loss alongside fat loss because total body mass loss includes both compartments. Published data suggests roughly 25 to 40 percent of weight lost on GLP-1 therapy is lean tissue if no strength training and adequate protein are added. Tesamorelin preserves or increases lean mass because it works through GH release. AOD-9604 specifically targets adipose without affecting muscle. Patients on GLP-1 therapy should pair with resistance training and 0.8 to 1.2 grams of protein per pound of target body weight to preserve lean mass.
- How much do weight loss peptides cost online?
- At RxPepsDirect, semaglutide starts at $25 per vial, tirzepatide starts at $45, AOD-9604 is $80, 5-Amino 1MQ is $80, tesamorelin is $100, Lean Stack (4-peptide combo) is $125, tesofensine is $2.25 per capsule, and Lipo-C is from $35 per 10mL vial. Plus a $39 one-time provider review. Subscription weight loss telehealth services typically charge $199 to $499 per month for the same compounded products bundled with their program management fee.
- Can I stack weight loss peptides?
- Yes, common stacks combine mechanisms. GLP-1 plus 5-Amino 1MQ pairs appetite suppression with metabolic boost. Tesamorelin plus AOD-9604 targets visceral fat through two pathways. Lean Stack combines AOD-9604, MOTs-C, tesamorelin, and ipamorelin in a single vial for patients who want broad metabolic action. RxPepsDirect providers screen stack combinations for interactions during intake. The cart limit is three SKUs per visit.
- Are compounded weight loss peptides FDA approved?
- Semaglutide and tirzepatide are FDA-approved as branded drugs (Ozempic, Wegovy, Mounjaro, Zepbound). The compounded versions dispensed by 503A pharmacies are legal under a patient-specific prescription per 21 U.S.C. 353a. Tesamorelin is FDA-approved as Egrifta and is also available as a compounded version through 503A pathway. AOD-9604, 5-Amino 1MQ, MOTs-C, and tesofensine are not FDA approved as branded drugs but are legal for prescription compounding by 503A pharmacies. The branded products are interchangeable in terms of active ingredient; the compounded versions use the same molecule at OBP wholesale pricing.
- How fast do weight loss peptides work?
- GLP-1 agonists produce noticeable appetite suppression within 1 to 2 weeks and measurable weight loss within 4 to 8 weeks. Most weight loss happens in the first 6 months of therapy. Tesamorelin produces measurable visceral fat reduction at 12 to 26 weeks; the effect is slower than GLP-1 appetite suppression but more targeted. Metabolic peptides (5-Amino 1MQ, AOD-9604) produce subjective effects at 4 to 8 weeks and measurable body composition changes at 8 to 12 weeks.
- Which weight loss peptide does not suppress appetite?
- Tesamorelin, AOD-9604, 5-Amino 1MQ, and MOTs-C work without appetite suppression. They target adipose metabolism, GH release, or mitochondrial function rather than the brain and gut pathways that GLP-1 agonists use. Patients who want fat loss without the GI side effects or hunger reduction of GLP-1 therapy can use these peptides as primary tools, though weight loss magnitude is smaller than with GLP-1s. Tesofensine works through dopamine, norepinephrine, and serotonin reuptake inhibition and does suppress appetite, though through a different mechanism than GLP-1s.
Continue reading